Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ImClone up on Erbitux news

IMCLE was up $4.75 (24%) to $24.60 on 5.1 million shares on Tuesday. The

Read the full 149 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE